Home » Newsletters » BioWorld Science

BioWorld Science

March 20, 2014

View Archived Issues

New approach to melanoma treatment: TR3-mediated autophagic cell death

Discovery of potent oral p53-Mdm2 inhibitors

Peanut allergy model created via bone marrow transplant

New study investigates third-generation CAR T-cell therapy with incorporated safety switch

Researchers at Merck & Co. design novel AMPK activators for diabetes

Array BioPharma and Genentech present new ERK inhibitors

Merck & Co. presents novel SYK inhibitors for the treatment of rheumatoid arthritis

Enrollment under way in Alcobra's phase III trial of MDX for adult ADHD

Compound library partnership established between Astellas and Daiichi Sankyo

Bristol-Myers Squibb presents data for BMS-903452

Sanofi Pasteur and SK Chemical collaborate on pneumococcal conjugate vaccine

biOasis Technologies, MedImmune sign agreement for second-generation brain delivery platform

TRPA1 antagonists described for the potential treatment of familial episodic pain syndrome

Chinese group presents novel agents for HIV and HBV infection

Researchers at the Virginia Commonwealth University disclose novel conjugates for cancer

Portola Pharmaceuticals begins phase III study of andexanet alfa

First patient enrolled in phase I study of AG-120

Dartmouth and Aeras to study new tuberculosis vaccine, DAR-901

Novel biomarker for colon cancer

Isis Pharmaceuticals begins phase I study of ISIS-ANGPTL3Rx to treat hyperlipidemia

AdvanDx submits application to FDA seeking approval of rapid MRSA test

Phase Ia results for HMS-5552 lead to initiation of phase Ib study

FDA approves Impavido for leishmaniasis

Emmaus Life Sciences reports topline data from phase III sickle cell disease trial

Merck & Co. initiates North American phase III development of SLIT tablet

Navidea Biopharmaceuticals discusses Lymphoseek MAA with EMA committee

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...